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1 ESGE suggests performing segmental biopsies (at least
two from each segment), which should be placed in differ-
ent specimen containers (ileum, cecum, ascending, trans-
Guideline
Table 1 s
Supplementary material is available under
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Adequate collection and handling of tissue samples during
endoscopy is fundamental in diagnosing pathology of the
digestive system. The aim of this guideline was to make
evidence-based recommendations on the indications and pro-
tocols for endoscopic tissue sampling for the most common
conditions in the upper and lower gastrointestinal tracts and
the hepatopancreatobiliary (HPB) tract. The upper gastrointes-
tinal and HPB tracts were covered in Part 1, which was pub-
lished separately [1].
Part 2 of this guideline will focus on the lower gastrointesti-
nal tract. Colonoscopy is one of the most exploited endoscopic
procedures for screening, diagnostic, and surveillance purpo-
ses. Despite the accuracy of endoscopy in detecting macro-
scopic lesions, several diseases require an optimized biopsy
protocol. This guideline aims to provide evidence-based tissue
sampling protocols for colonoscopy procedures performed in
patients with clinical signs of colitis, known inflammatory bowel
disease (IBD), including surveillance of pouch patients, and
those with potential premalignant lesions or colorectal cancer.
SOURCE AND SCOPE
This Guideline is an official statement of the European
Society of Gastrointestinal Endoscopy (ESGE). It provides
guidance on the collection and handling of tissue samples
during endoscopy of the lower gastrointestinal tract. The
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) system was adopted to define
the strength of recommendations and the quality of
evidence.
verse, descending, and sigmoid colon, and rectum) in
patients with clinical and endoscopic signs of colitis.
Weak recommendation, low quality of evidence.
2 ESGE recommends taking two biopsies from the right
hemicolon (ascending and transverse colon) and, in a
separate container, two biopsies from the left hemicolon
(descending and sigmoid colon) when microscopic colitis
is suspected.
Strong recommendation, low quality of evidence.
3 ESGE recommends pancolonic dye-based chromoendos-
copy or virtual chromoendoscopy with targeted biopsies of
any visible lesions during surveillance endoscopy in patients
with inflammatory bowel disease.
Strong recommendation, moderate quality of evidence.
4 ESGE suggests that, in high risk patients with a history of
colonic neoplasia, tubular-appearing colon, strictures,
ongoing therapy-refractory inflammation, or primary scle-
rosing cholangitis, chromoendoscopy with targeted biop-
sies can be combined with four-quadrant non-targeted
biopsies every 10 cm along the colon.
Weak recommendation, low quality of evidence.
5 ESGE recommends that, if pouch surveillance for dyspla-
sia is performed, visible abnormalities should be biopsied,
with at least two biopsies systematically taken from each
of the afferent ileal loop, the efferent blind loop, the pouch,
and the anorectal cuff.
Strong recommendation, low quality of evidence.
6 ESGE recommends that, in patients with known ulcerative
colitis and endoscopic signs of inflammation, at least two
biopsies be obtained from the worst affected areas for the
assessment of activity or the presence of cytomegalovirus;
for those with no evident endoscopic signs of inflamma-
tion, advanced imaging technologies may be useful in
identifying areas for targeted biopsies to assess histologic
remission if this would have therapeutic consequences.
Strong recommendation, low quality of evidence.
7 ESGE suggests not biopsying endoscopically visible in-
flammation or normal-appearing mucosa to assess disease
activity in known Crohn’s disease.
Weak recommendation, low quality of evidence.
8 ESGE recommends that adequately assessed colorectal
polyps that are judged to be premalignant should be fully
excised rather than biopsied.
Strong recommendation, low quality of evidence.
9 ESGE recommends that, where endoscopically feasible,
potentially malignant colorectal polyps should be excised
en bloc rather than being biopsied. If the endoscopist can-
not confidently perform en bloc excision at that time, care-
ful representative images (rather than biopsies) should be
taken of the potential focus of cancer, and the patient
should be rescheduled or referred to an expert center.
Strong recommendation, low quality of evidence.
10 ESGE recommends that, in malignant lesions not amen-
able to endoscopic excision owing to deep invasion, six
carefully targeted biopsies should be taken from the poten-
tial focus of cancer.
Strong recommendation, low quality of evidence.






























The European Society of Gastrointestinal Endoscopy (ESGE)
commissioned this Guideline (Guideline Committee Chair,
J. v. H.) and appointed a guideline leader (R.P.) who invited the
listed authors to participate in the project development. After
the project group had been assembled, task forces were
formed to define the key questions and PICOs (population, in-
tervention, comparator, outcome) in the upper gastrointesti-
nal, lower gastrointestinal, and HPB domains (Table 1 s, see
online-only Supplementary material). Literature searches and
reviews of relevant articles were performed between March
and September 2020. The available evidence was graded ac-
cording to the Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) system [2]. Based on the
available evidence, recommendations and suggestions were
drafted and discussed with the project group during online
meetings. Further details on the methodology of ESGE guide-
lines have been reported elsewhere [3].
In July 2021, a draft prepared by the leaders and coordinat-
ing team was sent to all group members. The manuscript was
also reviewed by two independent reviewers and sent for fur-
ther comments to the ESGE National Societies and individual
members. After agreement on a final version, the manuscript
was submitted to the journal Endoscopy for publication. All
authors agreed on the final revised manuscript. All recommen-
dations in this guideline are summarized in ▶Table1.
This Guideline was issued in 2021 and will be considered for
review and update in 2026, or sooner if new and relevant evi-
dence becomes available. Any updates to the Guideline in the
interim will be noted on the ESGE website: http://www.esge.
com/esge-guidelines.html.
3 Colitis
3.1 Clinical and endoscopic signs of colitis
In patients with clinical and endoscopic signs of colitis with-
out an already established diagnosis, it is recommended that at
least two biopsies be obtained from seven segments (terminal
ileum, cecum, ascending, transverse, descending, and sigmoid
colon, and rectum), including if some segments are endoscop-
ically normal. Biopsies should be placed into a separate contain-
er for each segment. This biopsy strategy increases the chance
of a reliable diagnosis, including where there is a suspicion of
Crohn’s disease or ulcerative colitis (UC) [4, 5]. In a prospective
consecutive cohort study, it was demonstrated that performing
segmental biopsies and informing the pathologist about the
endoscopic features and clinical data resulted in the etiology
of the colitis being correctly identified in 100% of cases. This
study included patients with IBD, infections, graft-versus-host
disease, microscopic colitis, nonsteroidal anti-inflammatory
drug (NSAID) colonopathy, and amyloidosis [4].
Because the mucosal changes on histology may appear sim-
ilar (e. g. in cases of infectious and ischemic colitis), clinical data
are indispensable for the pathologist and an integral part of
correctly diagnosing the etiology of the inflammation.
It is only where an endoscopic spot diagnosis (e. g. pseudo-
membranous colitis, ischemic colitis) can be made that seg-
mental biopsies may not be necessary.
RECOMMENDATIONS
ESGE suggests performing segmental biopsies (at least
two from each segment), which should be placed in dif-
ferent specimen containers (ileum, cecum, ascending,
transverse, descending, and sigmoid colon, and rectum)
in patients with clinical and endoscopic signs of colitis.
Weak recommendation, low quality of evidence.
ESGE suggests the pathologist should be informed of the
endoscopic features of the colitis and any relevant clinical
data.




ESGE European Society of Gastrointestinal Endoscopy
GRADE Grading of Recommendations Assessment,
Development and Evaluation
HGD high grade dysplasia
HPB hepatopancreatobiliary
IBD inflammatory bowel disease
LCI linked color imaging
LGD low grade dysplasia
MES Mayo endoscopic score
NBI narrow-band imaging
NHI Nancy histological index
NSAID nonsteroidal anti-inflammatory drug
OR odds ratio
PICaSSO Paddington International Virtual Chromoen-
doScopy ScOre
PICO population, intervention, comparator, outcome
PSC primary sclerosing cholangitis
RCT randomized controlled trial
RHI Robarts histopathology index
SES-CD Simple Endoscopic Score for Crohn’s disease
UC ulcerative colitis
UCEIS Ulcerative Colitis Endoscopic Index of Severity
WLE white-light endoscopy




























3.2 Clinical suspicion but no endoscopic signs of
colitis
Where the scenario is that there is a clinical suspicion of
colitis but with no clear endoscopic signs of colitis, microscopic
colitis must be ruled out. The diagnosis of the different sub-
types of microscopic colitis depends on the identification of
certain microscopic changes in the colonic mucosal biopsies
[6–8].
In collagenous colitis, the most typical feature on hematox-
ylin and eosin (H&E)-stained slides is an irregular thickening of
the subepithelial collagen layer beneath the basement mem-
brane: the normal thickness is 0–3µm, whereas in collagenous
colitis this increases to at least 10µm, measured on well-
oriented perpendicular sections. A Masson trichrome stain or
an immunohistochemical stain for tenascin can be useful an-
cillary techniques to reach the diagnosis. An associated in-
creased inflammatory cell infiltrate and possibly a detached
surface epithelium can be seen. Importantly, the thickened
subepithelial collagen layer may be unevenly distributed along
the colon (being most prominent proximally, while it can be
▶Table 1 Summarized recommendations for tissue sampling in the lower gastrointestinal tract.
Suspected diagnosis or
indication
Number and location of biopsies Remarks
Clinical and endoscopic signs
of colitis
Segmental biopsies (at least two from each segment) placed in
different specimen containers (ileum, cecum, ascending, trans-
verse, descending, and sigmoid colon, and rectum)
Inform the pathologist of the endoscopic
features of the colitis and relevant clinical
data
Clinical suspicion but no
endoscopic signs of colitis
Two biopsies from the left hemicolon (descending and sigmoid
colon) and two from the right hemicolon (ascending colon and
transverse colon)
Place biopsies from the left and right hemi-
colons into separate containers
Surveillance endoscopy in
patients with known IBD
Pancolonic dye-based or virtual chromoendoscopy with targe-
ted biopsies of any visible lesions
In high risk patients (history of colonic neoplasia, tubular-
appearing colon, strictures, ongoing therapy-refractory inflam-
mation, PSC), chromoendoscopy with targeted biopsies can be
combined with four-quadrant non-targeted biopsies every
10 cm along the colon
Surveillance endoscopy in
pouch patients
Biopsies of visible abnormalities and at least two biopsies from
each of the afferent ileal loop, the efferent blind loop, the
pouch, and the anorectal cuff
Place biopsies from different locations into
separate containers
Evaluation of disease activity
or remission in patients with
known ulcerative colitis
For patients with endoscopic signs of inflammation, at least two
biopsies from each segment, preferably from the worst affected
areas, to assess disease activity or for CMV
For patients with no evident endoscopic signs of inflammation,
advanced imaging technologies may be useful in identifying
areas for targeted biopsies to assess histologic remission if this
would have therapeutic consequences
Evaluation of disease activity
in patients with known
Crohn’s disease
No biopsies of endoscopically visible inflammation or normal-
appearing mucosa are recommended
Potentially premalignant
lesions
Adequately assessed colorectal polyps judged to be premalig-
nant should be fully excised rather than biopsied
Suspicion of colorectal
cancer
Where endoscopically feasible, potentially malignant colorectal
polyps should be excised en bloc rather than biopsied; if en bloc
excision is not possible, careful representative images should be
taken of the potential focus of cancer, and the patient should be
rescheduled or referred to an expert center
For malignant lesions that are not amenable to endoscopic
excision owing to deep invasion, six carefully targeted biopsies
should be taken from the potential focus of cancer
To reduce the risk of contamination and
tumor seeding, forceps and snares used to
sample or resect a potentially malignant
lesion should not be reused; wherever pos-
sible, cancer sampling should be deferred
until the end of the procedure
IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis; CMV, cytomegalovirus.
RECOMMENDATION
ESGE recommends taking two biopsies from the right
hemicolon (ascending and transverse colon) and, in a
separate container, two biopsies from the left hemicolon
(descending and sigmoid colon) when microscopic colitis
is suspected.
Strong recommendation, low quality of evidence.





























entirely absent in the sigmoid colon and rectum in up to a
third of cases) [7].
In lymphocytic colitis, the number of intraepithelial lympho-
cytes must be elevated above 20 per 100 surface epithelial cells
(normal value <5 per 100). There is an associated increase in
lamina propria inflammatory cells and possibly detachment of
the surface epithelium, but no thickening of the subepithelial
collagen layer. Lymphocytic colitis usually shows an even distri-
bution throughout the colon, but the diagnostic findings may
be patchy [7].
For the above-mentioned reasons, rectal biopsies alone ap-
pear insufficient for the exclusion of microscopic colitis and
sampling within the range of flexible sigmoidoscopy may be
inadequate. Therefore, a full ileocolonoscopy with biopsy sam-
pling of the right hemicolon (one biopsy from the ascending
colon and one biopsy from the transverse colon) and left hemi-
colon (one biopsy from the descending colon and one biopsy
from the sigmoid colon) should be performed [11, 12]. The
biopsies from the right and left hemicolon should be placed in
separate containers and labelled as such [7–14].
4 Inflammatory bowel disease
4.1 Surveillance endoscopy in patients with known
inflammatory bowel disease
Current guidelines advise surveillance colonoscopy in
patients with IBD be performed 8 years after the onset of the
colitis (with the exception of those with proctitis or Crohn’s
colitis limited to one segment) for early detection of premalig-
nant and malignant lesions [15]. Patients with longstanding UC
and Crohn’s colitis have an increased risk of developing colorec-
tal cancer (CRC) when compared with the general population
[16]. Disease extent, disease duration (CRC risk rises at a rate
of 0.5%–1% per year after a disease duration of 8–10 years),
degree of inflammation, presence of primary sclerosing cholan-
gitis (PSC), and family history of CRC are all associated with an
increased cancer risk [17, 18]. More recently, the presence of
post-inflammatory polyps was found not to be independently
associated with an increased risk of CRC [19]. Adequate bowel
preparation, meticulous inspection, and high resolution equip-
ment can optimize dysplasia detection [20, 21].
As compared with random biopsies on white-light endos-
copy (WLE), the use of chromoendoscopy with targeted biop-
sies has increased the diagnostic yield for dysplasia [17, 22,
23]. A meta-analysis, including two randomized controlled
trials (RCTs) showed a pooled incremental yield of chromoen-
doscopy over WLE for the detection of any grade of dysplasia
on a per-patient basis of 7% (95%CI 3.2%–11.3%) with a num-
ber needed to treat of 14.3 [22]. More recently, a network
meta-analysis of 27 studies showed that dye-based chromoen-
doscopy was associated with a higher likelihood of discovering
dysplastic lesions than WLE [24]. A recent multicenter RCT
showed no difference between the detection rate of colorectal
neoplasia when patients were randomized to high definition
WLE with random biopsy vs. high definition chromoendoscopy
with targeted biopsy [25]. Additionally, in a randomized non-
inferiority study, virtual chromoendoscopy or high definition
WLE was not inferior to dye-based chromoendoscopy for the
detection of colonic neoplastic lesions during surveillance colo-
noscopy [26]. A meta-analysis showed that, in RCTs, there was
only a small benefit of dye-based chromoendoscopy over
standard definition WLE, but no benefit over high definition
WLE [27].
A prospective study examined 1000 patients undergoing sur-
veillance colonoscopy for IBD. The standardized procedure was
chromoendoscopy with targeted biopsies or endoscopic resec-
tion and then quadrant random biopsies taken every 10 cm
[28]. An expert group of gastrointestinal pathologists agreed
on the diagnosis of neoplasia, graded according to the Vienna
classification as low grade dysplasia (LGD), high grade dysplasia
(HGD), or cancer (indefinite for dysplasia was not considered
neoplastic). A total of 140 neoplastic sites were found in 94
patients, 80% of these from targeted biopsies or resections
and 20% from random biopsies. The yield of neoplasia from
random biopsies was only 0.2% per biopsy and 1.2% per colo-
noscopy, but 12.8% per patient with neoplasia. Importantly,
dysplasia detected by random biopsies was associated with a
personal history of neoplasia, a tubular-appearing colon, and
the presence of PSC [28].
Another prospective multicenter RCT included 188 patients,
of which 94 were randomized to high definition virtual chromo-
endoscopy and 94 to high definition WLE [29]. Targeted and
quadrant non-targeted biopsies were taken in both arms. There
was no significant difference in terms of neoplasia detection
but, importantly, almost all neoplastic lesions were detected
on targeted biopsy or resection, with quadrant non-targeted
biopsies producing a negligible additional gain [29].
A recent retrospective cohort of 300 patients with colitis un-
dergoing chromoendoscopy or high definition endoscopy for
surveillance found that longer disease duration (odds ratio
[OR] 1.04, 95%CI 1.01–1.07), active inflammation (OR 2.89,
95%CI 1.26–6.67), and concomitant PSC (OR 3.66, 95%CI
1.21–11.08) were associated with the detection of dysplasia
on random biopsies, compared with visible lesions [30].
RECOMMENDATIONS
ESGE recommends pancolonic dye-based chromoendos-
copy or virtual chromoendoscopy with targeted biopsies
of any visible lesions during surveillance endoscopy in
patients with inflammatory bowel disease.
Strong recommendation, moderate quality of evidence.
ESGE suggests that, in high risk patients with a history of
colonic neoplasia, tubular-appearing colon, strictures,
ongoing therapy-refractory inflammation, or primary
sclerosing cholangitis, chromoendoscopy with targeted
biopsies can be combined with four-quadrant non-
targeted biopsies every 10 cm along the colon.
Weak recommendation, low quality of evidence.




























There is no strong evidence to recommend biopsies from
mucosa surrounding macroscopic lesions as the yield of these
biopsies is low and does not change the management of the
patient in comparison to the lesion itself [31]. In a retrospective
study of 56 patients with IBD undergoing removal of dysplastic
polyps, peripolyp biopsy specimens were assessed for dysplasia
[32]. The diagnostic yield for dysplasia was 3.2% and the pres-
ence of dysplasia was not associated with the risk of HGD or can-
cer during a median follow-up of 1.7 years. However, the grade
of dysplasia of the polyp itself was predictive of subsequent
advanced neoplasia. In line with this, in another retrospective
study, dysplasia was detected in 5% of biopsies collected from
the surroundings of dysplastic lesions and post-resection
surveillance did not reveal HGD or cancer [33]. Additionally, in a
study of 131 patients undergoing 302 polyp resections or biop-
sies, dysplasia in adjacent biopsies was detected in only two
patients (0.7%) and was endoscopically visible in both cases
[34].
4.2 Surveillance endoscopy in pouch patients
Current guidelines suggest pouch surveillance in high risk
patients [35, 36]. Epidemiologic data demonstrate an increased
risk of pouch neoplasia over time ranging from 0.9%–1% after 5
years to 4.2%–6.7% after 20 years [37–39]. Based on the avail-
able data, pouch surveillance in high risk patients after colect-
omy for neoplasia seems reasonable 10–15 years after pouch
construction. Available studies that have assessed the yield of
biopsies demonstrate no clear beneficial effect of targeted or
random biopsies for the identification of neoplasia in patients
with a relatively short follow-up after pouch construction [40–
45]. Most of these studies have however a relatively short
follow-up of less than 10 years after pouch construction, while
the epidemiologic data clearly indicate an increase in risk 15–
20 years after pouch construction.
A prospective non-randomized trial assessed the sequential
use of WLE and chromoendoscopy-targeted biopsies, followed
by four random biopsies systematically taken from the afferent
ileal loop, the efferent blind loop, the pouch, and the anorectal
cuff [40]. One lesion with LGD was found with WLE. Chromo-
endoscopy revealed 14 suspicious lesions but none of them
contained dysplasia. On the other hand, 672 random biopsies
showed LGD in three biopsies (0.45%). As the mean follow-up
was only 8.6 years, it does not seem useful to perform biopsies
early after pouch reconstruction. On the other hand,
chromoendoscopy-targeted biopsies were insufficient to find
the dysplasia that was present in these patients.
The additional need for random biopsies was illustrated in a
retrospective study with 96 patients with pouch polyps and 998
without polyps (total of 1096 patients with 9 years of follow-up
after pouch construction) [41]. In the polyp group, 3/96
patients had dysplasia (2 indefinite and 1 LGD), whereas 2/998
patients in the group without inflammatory polyps had neopla-
sia, but this was HGD and cancer found on non-targeted biop-
sies. Therefore, it seems insufficient to only target visible ab-
normalities.
Based on the available data, we recommend that, if one
chooses to follow up pouch constructions in high risk patients
with previous dysplasia, cancer, or PSC, at least after 10 years
this should be by a combination of targeted and random biop-
sies, as data suggest that taking biopsies from visible abnorm-
alities alone is insufficient.
4.3 Evaluation of disease activity or remission
in patients with known ulcerative colitis
Endoscopy and histology are pivotal in assessing the activity
of disease in UC. There is a growing body of evidence that histo-
logic activity or histologic healing/remission may be an impor-
tant therapeutic end point associated with improved patient
outcome. In addition, histologic activity or chronic inflamma-
tion is likely to be an important risk factor for UC-associated
neoplasia. Definitions for histologic remission of the mucosa in-
clude histologic normalization with absence of inflammation;
absence of intraepithelial and lamina propria neutrophils/ero-
sion/ulceration. Several studies and a meta-analysis have
shown that 18%–24% of UC patients with endoscopic remission
still have histologic changes and inflammation [46]. It is there-
fore suggested that assessment of histologic activity provides
clinically important prognostic information, beyond that of
endoscopic remission or clinical remission [46].
Several studies have aimed to correlate endoscopic activity
with histologic activity and generally the relationship has been
modest at best. However, these studies have been heteroge-
neous as most of them were single-center retrospective or pro-
spective observational studies. This has resulted in variance of
concordance between endoscopic activity and histologic activi-
ty. The likely reason for this disparity is that these studies have
RECOMMENDATIONS
ESGE recommends that, in patients with known ulcerative
colitis and endoscopic signs of inflammation, at least two
biopsies be obtained from the worst affected areas for
the assessment of activity or the presence of cyto-
megalovirus.
Strong recommendation, low quality of evidence.
ESGE recommends that, in patients with known ulcerative
colitis and no evident endoscopic signs of inflammation,
advanced imaging technologies may be useful in identify-
ing areas for targeted biopsies to assess histologic remis-
sion if this would have therapeutic consequences.
Strong recommendation, low quality of evidence.
RECOMMENDATION
ESGE recommends that, if pouch surveillance for dyspla-
sia is performed, visible abnormalities should be biop-
sied, with at least two biopsies systematically taken from
each of the afferent ileal loop, the efferent blind loop, the
pouch, and the anorectal cuff.
Strong recommendation, low quality of evidence.





























used variable and nonvalidated endoscopic or histologic indices
for the comparison [47–50]. Many histologic indices have been
developed in the past decades to assess activity of the disease
in UC, but only two have been fully validated and tested for re-
sponsiveness, namely the Nancy histological index (NHI) [51]
and the Robarts histopathology index (RHI) [52]. Scores to
endoscopically assess disease activity include the Mayo Endo-
scopic Score (MES), which is partially validated and is widely
used by gastroenterologists for its simplicity [53], and the
Ulcerative Colitis Endoscopic Index of Severity [UCEIS], which
was validated in three independent cohorts and is mainly used
in clinical trials [54].
In a single-center prospective observational study, the over-
all correlation between the validated UCEIS and RHI was nu-
merically greater [r=0.86, 95%CI 0.80–0.90; P<0.001] than be-
tween the UCEIS and NHI [r=0.84, 95%CI 0.76–0.89; P<0.001]
[55]. In contrast, in a recent multicenter international prospec-
tive study, the correlations between the endoscopic scores and
Riley histologic score in quiescent UC were low [56]. Recently a
large multicenter international “real life” study demonstrated
that the MES, UCEIS, and the newly validated virtual chromoen-
doscopy score PICaSSO (Paddington International Virtual Chro-
moendoScopy ScOre) [57] correlated strongly with several his-
tologic scores. Correlation of the PICaSSO with all histology
scores was statistically superior to both the MES and UCEIS [57].
In view of the current data, biopsies are still recommended
with a minimum of two biopsies from either the worst affected
or the most representative area of mucosal healing, preferably
at the edge of any ulcers. Histologic assessment of biopsies can
be used to assess disease activity, the presence of cytomegalo-
virus, and histologic healing, to optimize therapy by either
escalation or exit strategies, to predict long-term adverse
outcome, and to manage patients to achieve their treatment
target.
The endoscopic differences between quiescent, mild, and
patchy activity of the disease are often difficult to detect, espe-
cially when using standard WLE. New advanced high definition
endoscopic technologies and optical diagnosis and enhance-
ment techniques, such as narrow-band imaging (NBI; Olympus
Japan), iSCAN (iSCAN-OE; Pentax, Japan), linked color imaging
(LCI; Fujifilm), blue-light imaging (BLI; Fujifilm, Japan), confocal
laser endomicroscopy (CLE; Mauna Kea, France), and endocyto-
scopy (Olympus, Japan) can provide a better definition of the
mucosal and vascular architecture (▶Fig. 1 and ▶Fig. 2). In ad-
dition, artificial intelligence (AI) may play an important role in
assessing histologic remission, but its use should first be pro-
spectively validated. Although advanced imaging techniques
cannot yet replace real histology, these techniques may be use-
ful in identifying areas for targeted biopsies.
4.4 Evaluation of disease activity in patients with
known Crohn’s disease
A recent systematic review summarized all the histologic
scores that are used to score Crohn’s disease activity histologi-
cally. This included 14 studies mentioning 13 different scores.
The most commonly used score is the Global Histological Activi-
ty Score (GHAS), which has been modified in six other scores.
The main problem is that none of these scores have been pro-
spectively validated against endoscopic activity alone. Some
scores are validated against clinical disease activity only [58].
▶ Fig. 1 Use of advanced imaging techniques in ulcerative colitis. a–c Endoscopic appearance in quiescent ulcerative colitis imaged by: a white-
light endoscopy (WLE); b i-scan 2 mode; c i-scan 3 mode; with d histological appearance on biopsy. e–g Endoscopic appearance in severe
ulcerative colitis imaged by: e WLE; f i-scan 2 mode; g i-scan 3 mode; with h histological appearance on biopsy.
RECOMMENDATION
ESGE suggests not biopsying endoscopically visible
inflammation or normal-appearing mucosa to assess
disease activity in known Crohn’s disease.
Weak recommendation, low quality of evidence.




























▶ Fig. 2 Use of advanced imaging techniques in ulcerative colitis. a–d Endoscopic images demonstrating mild activity of ulcerative colitis
imaged by: a high definition white-light endoscopy (WLE); b linked color imaging (LCI); c blue-light imaging (BLI); d BLI, which is used to guide
biopsy sampling. e–h Endoscopic images showing moderate activity of ulcerative colitis imaged by: e high definition WLE; f LCI; g BLI; h BLI, with
a biopsy being obtained from the worst affected area.
▶ Fig. 3 Endoscopic images of potentially premalignant lesions in the colon and colorectal cancer showing: a, b a non-advanced tubular ade-
noma with low grade dysplasia (LGD) on: a near-focus high definition white-light endoscopy (WLE); b narrow-band imaging (NBI); c, d a non-
advanced tubulovillous adenoma with LGD on: c high definition WLE; d linked color imaging; e–h an advanced lesion of > 10mm that is carefully
assessed, after washing, and found to have no foci suspicious of invasive malignancy (with final histology showing a tubular adenoma with LGD)
on: e, g high definition WLE; f, h blue-light imaging; i, j an advanced lesion appearing atypical and suspicious for neoplasia on: i high definition
WLE; j near-focus NBI where there is a suspicion of deep invasion based on the vascular and mucosal pattern (NICE type 3, JNET type 3);
k, l advanced colorectal cancer, T2N1. Source: Dr. M. van der Vlugt and Dr. B.A.J. Bastiaansen.





























The studies that are available have assessed, usually in retro-
spect, the correlation between endoscopic activity and histo-
logy [59–67]. The Simple Endoscopic Score for Crohn’s disease
(SES-CD) is the most commonly used endoscopic score. The
correlations between histologic inflammation and SES-CD
have ranged from very poor (r=0.182) to good (r>0.79). One
interesting study assessed the importance of the location, in re-
lation to the ulcer, from which the biopsy was taken. Interest-
ingly, a significant decrease in histologic disease activity could
be found with increasing distance from the edge of the ulcer.
Even in close proximity, namely 7–8mm from the edge, histo-
logic inflammation was decreased. In addition, only a poor con-
cordance in terms of remission was found between the histo-
logic scores and the SES-CD [59].
In view of the lack of sufficient validation of histologic
scores, variable correlation with endoscopic disease activity,
and variability of biopsies even in close proximity to an ulcer, it
seems that additional biopsies to assess histologic disease
activity contribute very little to the clinical management of
patients with a confirmed diagnosis of Crohn’s disease. In addi-
tion, one may wonder if a mucosal biopsy is representative of a
transmural disease. Because Crohn’s disease has a patchy distri-
bution, it is also possible that access to the most inflamed areas
will be compromised by the presence of strictures. In this case,
random biopsies of a less inflamed area accessed by colonos-
copy or enteroscopy will not reflect the actual state of inflam-
mation of the patient.
5 Potentially premalignant lesions
and colorectal cancer
5.1 Potentially premalignant lesions
5.1.1 Non-advanced lesions
In general, colorectal polyps should be fully excised rather than
biopsied. This approach allows definitive histopathologic
evaluation and should also be curative. However, some diminu-
tive (≤5mm) polyps, specifically rectal hyperplastic polyps,
carry no malignant potential and, therefore, provided optical
assessment is consistent with this diagnosis, these polyps
need neither removal nor tissue sampling; where doubt
remains, they should be fully excised (▶Fig. 3) [68].
Whilst most other diminutive polyps are premalignant and
should therefore be resected, endoscopic assessment of sur-
face features (morphology, pit pattern, and vascular pattern)
may accurately predict histology when performed by appropri-
ately trained endoscopists, removing the need for histologic as-
sessment of the resected specimen: ESGE suggests that virtual
chromoendoscopy and dye-based chromoendoscopy can be
used, under strictly controlled conditions, for real-time optical
diagnosis of diminutive colorectal polyps and can replace histo-
pathologic diagnosis [69]. ESGE also suggests the possible
incorporation of computer-aided characterization of lesions
during colonoscopy, if acceptable and reproducible accuracy
for colorectal neoplasia is demonstrated in high quality multi-
center in vivo clinical studies [69].
5.1.2 Advanced lesions
Large (> 10mm) or atypical colorectal lesions (JNET type 2B or
type 3 [70]; NICE classification type 3 [71]) require careful
endoscopic assessment, with adequate washing and thorough
inspection of the entire lesion, to identify potential foci of inva-
sive malignancy (▶Fig. 3). This is aided by the use of high def-
inition endoscopes, in combination with (virtual) chromoen-
doscopy [69, 72]. Biopsies are not required if the endoscopist
has thoroughly interrogated the lesion and has not identified
any atypical features. This information can be supplemented
with photographs or a video, which are usually more meaning-
ful than isolated biopsies.
5.2 Suspicion of colorectal cancer
5.2.1 Biopsy tethering
If a lesion may be amenable to endoscopic removal, biopsies
should be used with caution as there is a risk of submucosal te-
thering due to fibrosis, rendering the lesion unresectable [72].
The risk of tethering is highest when biopsies are taken from
flat lesions or at the periphery of a lesion, and is even higher if
a snare is used to partially resect or sample a lesion [68, 73]. Of
interest, one study found that tethering only occurred 3 weeks
RECOMMENDATIONS
ESGE recommends that, where endoscopically feasible,
potentially malignant colorectal polyps should be excised
en bloc rather than being biopsied. If the endoscopist
cannot confidently perform en bloc excision at that
time, careful representative images (rather than biop-
sies) should be taken of the potential focus of cancer,
and the patient should be rescheduled or referred to an
expert center.
Strong recommendation, low quality of evidence.
ESGE recommends that, in malignant lesions not amen-
able to endoscopic excision owing to deep invasion, six
carefully targeted biopsies should be taken from the
potential focus of cancer.
Strong recommendation, low quality of evidence.
ESGE recommends that, to reduce the risk of contamina-
tion and tumor seeding, forceps and snares used to
sample or resect a potentially malignant lesion should
not be reused during that procedure and, wherever possi-
ble, cancer sampling should be deferred until the end of
procedure.
Strong recommendation, low quality of evidence.
RECOMMENDATION
ESGE recommends that adequately assessed colorectal
polyps that are judged to be premalignant should be fully
excised rather than biopsied.
Strong recommendation, low quality of evidence.




























after biopsy [74]. Therefore, if the endoscopist cannot con-
fidently perform en bloc excision during endoscopy (e. g. be-
cause of lack of experience, lack of patient consent, or use of
anticoagulant therapy), careful representative images (rather
than biopsies) should be taken of the potential focus of cancer,
and the patient should be rescheduled or referred to an expert
center.
5.2.2 Underdiagnosis
Biopsy sampling of advanced colorectal lesions carries the risk
of missing the malignant focus within a polyp as only a small
portion of the lesion is sampled. Studies of biopsy sampling of
malignant colorectal polyps have reported false negative rates
of 18.5%–86% [75–78]. Therefore, where the endoscopist is
adequately experienced and confident that they can remove a
suspicious lesion en bloc, this is usually the best strategy as it
permits histologic assessment of the entire lesion, thereby
minimizing the risk of underdiagnosis [78]. However, for highly
suspicious lesions or where en bloc resection is not possible,
biopsy sampling may be required (▶Fig. 3). In this case, after
careful inspection of the entire lesion, biopsies should be tar-
geted to the area exhibiting features indicative of cancer, rather
than taking non-targeted (random) biopsies of the lesion [72].
5.2.3 High grade dysplasia on biopsy
Particular caution should be given to the interpretation of HGD
on a superficial biopsy of a lesion (as opposed to HGD seen in a
fully histologically assessed polypectomy specimen), as there is
an increased risk of malignancy within the lesion; the lesion
should be assumed to be malignant until proven otherwise
[79].
5.2.4 Number of biopsies
Several studies have assessed the optimal number of biopsy
specimens to reduce the cancer miss rate. One study of 60 can-
cers found that the first four biopsies identified 41 cancers,
whilst taking six biopsies identified 47 cancers [80]. No addi-
tional cancers were identified by taking further biopsies (up to
10 in total), but adding in cytology detected an additional eight
cancers; five cancers remained undiagnosed despite biopsies
and cytology. The authors concluded that the combination of
cytology and four to six biopsies was recommended. Another
study of 32 patients with advanced colon cancer revealed that
the positive diagnosis rates for the first, second, and third biop-
sies were 78.1%, 87.5%, and 93.8% [81]. Further biopsies did
not increase positive diagnosis cumulative rates, leading to the
recommendation that three or four biopsies should be taken.
Reinforcing the need for careful assessment and targeted
biopsies, a study demonstrated that the implementation of a
quality improvement program increased the CRC yield of histo-
logic sampling from 61% to 92% [82].
5.2.5 Contamination and tumor seeding
Another consideration regarding the biopsying of malignant
lesions is the small risk of “carry-over” between specimens if a
cancer is biopsied before a benign polyp, causing diagnostic
confusion [68]. Furthermore, a recent study demonstrated
that the colonoscope working channel became contaminated
with viable tumor cells during biopsy collection and that subse-
quent instruments introduced through the channel became
contaminated with cells that were shown to maintain their pro-
liferative potential [83]. They also identified an identical molec-
ular signature in primary and metachronous colorectal tumors
where the most likely etiology was tumor seeding, concluding
that, although the possibility of iatrogenic seeding seemed
low, it was a potentially preventable cause of metachronous
CRC, which could be reduced by simple adaptations, such as
changing the order of procedures (e. g. tattooing the site be-
fore sampling the cancer).
Disclaimer
The legal disclaimer for ESGE guidelines [84] applies to this
Guideline.
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